ReviewAnnals of general psychiatry2020
Neurocognitive impairment and evidence-based treatment options in Bipolar disorder.
Review in Annals of general psychiatry, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Factors Associated With Insight Toward Illness in Patients With Bipolar Disorder Type 1 in Manic Episodes.Alpha psychiatry · 2025Article
- The Big Five as Predictors of Cognitive Function in Individuals with Bipolar Disorder.Brain sciences · 2023Article
- Electroconvulsive therapy combined with lithium developed reversible pure anomic aphasia: a case report.BMC psychiatry · 2022Article
- Prevalence, profile and associations of cognitive impairment in Ugandan first-episode psychosis patients.Schizophrenia research. Cognition · 2022Article
- Association of Lithium and Second-Generation Antipsychotics with Neurocognition in Youth with Bipolar Disorder.Journal of child and adolescent psychopharmacology · 2022Article
- Calcium imaging reveals depressive- and manic-phase-specific brain neural activity patterns in a murine model of bipolar disorder: a pilot study.Translational psychiatry · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe current paper briefly summarizes the literature on the neurocognitive deficit and its treatment in BD patients.
methodsThe material was chosen on the basis of previous systematic reviews the author has taken part in.
resultsThe data so far suggest that the deficit is qualitatively similar but quantitatively milder in comparison to schizophrenia, it is present already since the first episode, is weakly related to mood symptoms and somewhat stronger to psychotic symptoms, it probably determines much of the disability and treatment is problematic. This deficit is also present during periods of euthymia. The possible adverse effect of psychotropic medication is rather small if any at all and is confounded by the specific clinical symptoms, for which medication is used for their treatment. This is especially true concerning antipsychotics and psychotic symptoms. The origin and the etiopathogenesis of the core neurocognitive impairment remain elusive. The presence of a neurodegenerative and of a neurodevelopmental component has both data in favor and against and they are both the focus of debate.
conclusionsTreatment of the neurocognitive deficit and restoration of functioning is problematic. The data are limited and treatment options are few and with a weak overall effect. Pharmacological treatments, ECT and rTMS present some hard data, while the literature is inconclusive concerning psychotherapeutic interventions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.